Dexrazoxane Reduces Short-Term Anthracycline-Associated Cardiac Dysfunction in Pediatric AML
Pediatric patients with AML may benefit from dexrazoxane as a cardioprotectant during first-line anthracycline therapy.
Dibash Kumar Das, PhD
Dibash K. Das serves as medical editor for Gastroenterology Advisor and oversees the day-to-day operation. He holds a Ph.D. in molecular, cellular, and developmental biology from the CUNY Graduate Center and an advanced certificate in clinical and translational investigation from Weill Cornell Medicine.
